1,798
Views
26
CrossRef citations to date
0
Altmetric
Research Article

Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles

, , &
Pages 206-213 | Received 10 Nov 2013, Accepted 30 Dec 2013, Published online: 29 Jan 2014
 

Abstract

Context: Docetaxel is now a major antitumor drug in clinical use for the treatment of a variety of tumors. The ethanol/Tween 80 solvent required in the formulation to increase the docetaxel solubility is at least partly responsible for the hypersensitivity reaction, decreased uptake by tumor tissue, and increased exposure to other body compartments.

Objective: The present study was aimed at developing hydrosoluble DTX-FA-HSANPs targeting tumor cells and to investigate antitumor activities of the nanoparticles.

Materials and methods: The DTX-HSANPs were prepared using a desolvation technique and the carboxylic groups of NHS-folate were conjugated with the amino groups of the human serum albumin nanoparticles, and studied their size and zeta potential, drug loading efficiency, surface morphology, release properties in vitro, and antitumor activities.

Results: The spherical nanoparticles obtained were negatively charged with a zeta potential of about −30 mV and characterized around 150 nm with a narrow size distribution. Drug loading efficiency was approximately 17.2%. The folate-decorated nanoparticles targeted a human hepatoma cell line effectively. The in vitro drug release of DTX-FA-HSANPs in the first 96 h corresponded with the following equation: Q = 18.87851 − 0.13866t + 0.21276t2 − 0.00704t3 + 0.0000847854t4 − 0.00000034991t5 (R2 = 0.98155). Moreover, the in vitro antitumor activities of DTX-FA-HSANPs were close to the activities of the positive control (docetaxel). The in vivo inhibition ratios of DTX-FA-HSANPs and docetaxel were 66.2% and 59.5%, respectively, at a dose of 5 mg/kg.

Discussion and conclusion: In light of the observed antitumor activities, it would be of considerable interest to collect sufficient data for the clinical application of docetaxel-loaded nanoparticles.

Acknowledgements

The authors also gratefully acknowledge Mr. Chao Xu, Mr. Yan Hu, and Dr. Dongmei Zhao for technical assistance in experiments.

Declaration of interest

The authors report no conflict of interest in this work. The authors would also like to acknowledge the financial support from, the Fundamental Research Funds for the Central Universities (DL12EA01-03), the Fundamental Research Funds for the Central Universities (DL13CA11), Heilongjiang Postdoctoral Grant (LBH-Z10282), the Special Fund for Forestry Scientific Research in the Public Interest (201204601), the “Twelfth Five-Year” National Science and technology support program in rural areas (2012BAD21B0501-11).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.